LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the successful pricing of $400 million aggregate principal amount of its 2.50% Convertible Senior Notes due 2017. Cubist has granted the underwriters an option to purchase up to an additional $50 million aggregate principal amount of the notes.
